別品名 |
[(1R)-3-methyl-1-[[(2S)-3-phenyl-2-(pyrazine-2-carbonylamino)propanoyl]amino]butyl]boronic acid; Boronic acid, B-[(1R)-3-methyl-1-[[(2S)-1-oxo-3-phenyl-2-[(2-pyrazinylcarbonyl)amino]propyl]amino]butyl]-; Boronic acid, [(1R)-3-methyl-1-[[(2S)-1-oxo-3-phenyl-2-[(pyrazinylcarbonyl)amino]propyl]amino]butyl]- (9CI); Boronic acid, [3-methyl-1-[[1-oxo-3-phenyl-2-[(pyrazinylcarbonyl)amino]propyl]amino]butyl]-, [S-(R*,S*)]-; Bortezomib; DPBA; LDP 341; MG 341; MLN 341; NSC 681239; PS 314; PS 341; PS 341 (pharmaceutical); Radiciol; Velcade
|
分子量 |
384.24
|
CAS RN® |
179324-69-7
|
構造 |
C19 H25 B N4 O4
|
溶媒 |
Chloroform (Slightly), DMSO (Slightly), Methanol (Slightly)
|
使用目的 |
Bortezomib is the first proteasome inhibitor to be approved by the US FDA for multiple myeloma, a blood cancer. A reversible inhibitor of the 26S proteasome-a barrel-shaped multiprotein particle found in the nucleus and cytosol of all eukaryotic cells. Targets the ubiquitin-proteasome pathway.
|
その他 |
[融点]>120℃ (dec.) [性状]White to Off-White Solid [安定性]Hygroscopic and Moisture Sensitive
|
参考文献 |
Nawrocki, S.T., et al: Cancer Research, 65, 11510 (2005); Drahl C.: Chem. and Eng. News, 87, 41 (2009)
|
※サムネイル画像をクリックすると拡大画像が表示されます。
|
|
|
メーカー |
品番 |
包装 |
TRC
|
B675700
|
100 MG
|
※表示価格について
販売状況 |
長期B.O、納期未定
|
当社在庫 |
なし
|
納期目安 |
納期未定
|
法規制 |
化管
|
保存温度 |
-20℃
|
|